Previous 10 | Next 10 |
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) ( OTCQB:OTLC ), developer of treatments for rare and orphan indications, including Parkinson Disease and DIPG, today announced that th...
Oncotelic Therapeutics press release ( OTCQB:OTLC ): Q2 Net profit of $15.97M “With the JV transaction, commencing Q2 2022, we have recorded a one-time profit of approximately $16 million, primarily on the gain on transfer of OT-101 to the JV of approximately $17.0 mill...
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 million Reduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS, Calif., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (...
AGOURA HILLS, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced that th...
AGOURA HILLS, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced tha...
AGOURA HILLS, Calif., June 15, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced tha...
Fosun Pharma acquired China rights to a novel broad cancer immunotherapy candidate from VerImmune of Baltimore in a $125 million agreement. Oncotelic Therapeutics, a South San Francisco company, formed a Hong Kong JV with Dragon Overseas Capital to develop TGF-β therapeutics. ...
Clinical-stage biotech Oncotelic Therapeutics (OTCQB:OTLC) announced on Wednesday that the Food and Drug Administration (FDA) cleared the Phase 2 trial protocol for the company’s lead candidate OT-101 in combination with Merck’s (MRK) Keytruda in mesothelioma. The company plans ...
AGOURA HILLS, Calif., May 25, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, including Parkinson Disease and various cancers, today announced the cl...
Mateon Therapeutics press release (OTCQB:OTLC): Q1 net loss of $5.09M. For further details see: Mateon Therapeutics reports Q1 results
News, Short Squeeze, Breakout and More Instantly...
Oncotelic Therapeutics Inc Company Name:
OTLC Stock Symbol:
OTCMKTS Market:
Oncotelic Therapeutics Inc Website:
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science & Technology (IDDST) (Europe), June 17-19, 2024 at Budapest, Hungary. ...
AGOURA HILLS, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will be participating at the BIO International 2024 meeting on June3-6, San Diego. The BIO International Convention is the largest and most comprehensive event ...
AGOURA HILLS, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its Chief Clinical Officer- Dr. Anthony Maida will be participating at the ASCO 2024 meeting. Abstract: e16318. Meta-analysis comparing the incidence of serious adverse events, ov...